Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation

Bruce C. Turner, Andrew A. Gumbs, Darryl Carter, Peter M. Glazer, Bruce G. Haffty

Research output: Contribution to journalArticle

Abstract

Purpose: The purpose of this study was to determine the prognostic significance of cyclin D1 (cycD1) levels in ipsilateral breast tumor recurrence (IBTR) following lumpectomy and radiation therapy. Methods and Materials: A total of 98 patients (49 patients with IBTR and 49 matched cases without IBTR) selected from our conservatively treated breast cancer population served as the patient population for the current study. All patients were treated with lumpectomy followed by radiation therapy to the intact breast to a total median dose of 64 Gy. The patients were followed in our clinic with a median follow-up of 13 years. Immunohistochemical analysis of cycD1 in these 98 early-stage breast cancer patients was performed using a polyclonal antibody generated against the human cycD1 protein. All clinical, pathologic, and molecular variables were entered into a computerized data base for statistical analysis. Results: Low levels of immunohistochemically detected cycD1 protein correlated with IBTR (p = 0.001), but there was no association between cycD1 protein levels and metastatic disease, axillary lymph node involvement, distant disease-free survival (DDFS), and overall survival (OS). Subgroup analysis revealed that for early breast tumor relapses (within 4 years of initial breast tumor diagnosis), low levels of cycD1 were associated with IBTR (p = 0.004), but cycD1 expression was not prognostic for IBTR from breast cancer patients with late relapses (p = NS). Conclusion: These studies provide in vivo evidence for the prognostic and biologic significance of cycD1 expression in determining response to radiation therapy in breast cancer patients. Copyright (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)1169-1176
Number of pages8
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume47
Issue number5
DOIs
StatePublished - Jul 15 2000
Externally publishedYes

Fingerprint

Segmental Mastectomy
Cyclin D1
breast
cancer
Radiation
Breast Neoplasms
Recurrence
radiation
tumors
Radiotherapy
radiation therapy
proteins
Proteins
lymphatic system
data bases
subgroups
antibodies
Population
Disease-Free Survival
statistical analysis

Keywords

  • Breast cancer
  • Cell cycle regulator
  • Cyclin D1
  • Radiosensitivity

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation. / Turner, Bruce C.; Gumbs, Andrew A.; Carter, Darryl; Glazer, Peter M.; Haffty, Bruce G.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 47, No. 5, 15.07.2000, p. 1169-1176.

Research output: Contribution to journalArticle

Turner, Bruce C. ; Gumbs, Andrew A. ; Carter, Darryl ; Glazer, Peter M. ; Haffty, Bruce G. / Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation. In: International Journal of Radiation Oncology, Biology, Physics. 2000 ; Vol. 47, No. 5. pp. 1169-1176.
@article{b512fd471e094851a003511cdea3badc,
title = "Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation",
abstract = "Purpose: The purpose of this study was to determine the prognostic significance of cyclin D1 (cycD1) levels in ipsilateral breast tumor recurrence (IBTR) following lumpectomy and radiation therapy. Methods and Materials: A total of 98 patients (49 patients with IBTR and 49 matched cases without IBTR) selected from our conservatively treated breast cancer population served as the patient population for the current study. All patients were treated with lumpectomy followed by radiation therapy to the intact breast to a total median dose of 64 Gy. The patients were followed in our clinic with a median follow-up of 13 years. Immunohistochemical analysis of cycD1 in these 98 early-stage breast cancer patients was performed using a polyclonal antibody generated against the human cycD1 protein. All clinical, pathologic, and molecular variables were entered into a computerized data base for statistical analysis. Results: Low levels of immunohistochemically detected cycD1 protein correlated with IBTR (p = 0.001), but there was no association between cycD1 protein levels and metastatic disease, axillary lymph node involvement, distant disease-free survival (DDFS), and overall survival (OS). Subgroup analysis revealed that for early breast tumor relapses (within 4 years of initial breast tumor diagnosis), low levels of cycD1 were associated with IBTR (p = 0.004), but cycD1 expression was not prognostic for IBTR from breast cancer patients with late relapses (p = NS). Conclusion: These studies provide in vivo evidence for the prognostic and biologic significance of cycD1 expression in determining response to radiation therapy in breast cancer patients. Copyright (C) 2000 Elsevier Science Inc.",
keywords = "Breast cancer, Cell cycle regulator, Cyclin D1, Radiosensitivity",
author = "Turner, {Bruce C.} and Gumbs, {Andrew A.} and Darryl Carter and Glazer, {Peter M.} and Haffty, {Bruce G.}",
year = "2000",
month = "7",
day = "15",
doi = "10.1016/S0360-3016(00)00525-3",
language = "English (US)",
volume = "47",
pages = "1169--1176",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation

AU - Turner, Bruce C.

AU - Gumbs, Andrew A.

AU - Carter, Darryl

AU - Glazer, Peter M.

AU - Haffty, Bruce G.

PY - 2000/7/15

Y1 - 2000/7/15

N2 - Purpose: The purpose of this study was to determine the prognostic significance of cyclin D1 (cycD1) levels in ipsilateral breast tumor recurrence (IBTR) following lumpectomy and radiation therapy. Methods and Materials: A total of 98 patients (49 patients with IBTR and 49 matched cases without IBTR) selected from our conservatively treated breast cancer population served as the patient population for the current study. All patients were treated with lumpectomy followed by radiation therapy to the intact breast to a total median dose of 64 Gy. The patients were followed in our clinic with a median follow-up of 13 years. Immunohistochemical analysis of cycD1 in these 98 early-stage breast cancer patients was performed using a polyclonal antibody generated against the human cycD1 protein. All clinical, pathologic, and molecular variables were entered into a computerized data base for statistical analysis. Results: Low levels of immunohistochemically detected cycD1 protein correlated with IBTR (p = 0.001), but there was no association between cycD1 protein levels and metastatic disease, axillary lymph node involvement, distant disease-free survival (DDFS), and overall survival (OS). Subgroup analysis revealed that for early breast tumor relapses (within 4 years of initial breast tumor diagnosis), low levels of cycD1 were associated with IBTR (p = 0.004), but cycD1 expression was not prognostic for IBTR from breast cancer patients with late relapses (p = NS). Conclusion: These studies provide in vivo evidence for the prognostic and biologic significance of cycD1 expression in determining response to radiation therapy in breast cancer patients. Copyright (C) 2000 Elsevier Science Inc.

AB - Purpose: The purpose of this study was to determine the prognostic significance of cyclin D1 (cycD1) levels in ipsilateral breast tumor recurrence (IBTR) following lumpectomy and radiation therapy. Methods and Materials: A total of 98 patients (49 patients with IBTR and 49 matched cases without IBTR) selected from our conservatively treated breast cancer population served as the patient population for the current study. All patients were treated with lumpectomy followed by radiation therapy to the intact breast to a total median dose of 64 Gy. The patients were followed in our clinic with a median follow-up of 13 years. Immunohistochemical analysis of cycD1 in these 98 early-stage breast cancer patients was performed using a polyclonal antibody generated against the human cycD1 protein. All clinical, pathologic, and molecular variables were entered into a computerized data base for statistical analysis. Results: Low levels of immunohistochemically detected cycD1 protein correlated with IBTR (p = 0.001), but there was no association between cycD1 protein levels and metastatic disease, axillary lymph node involvement, distant disease-free survival (DDFS), and overall survival (OS). Subgroup analysis revealed that for early breast tumor relapses (within 4 years of initial breast tumor diagnosis), low levels of cycD1 were associated with IBTR (p = 0.004), but cycD1 expression was not prognostic for IBTR from breast cancer patients with late relapses (p = NS). Conclusion: These studies provide in vivo evidence for the prognostic and biologic significance of cycD1 expression in determining response to radiation therapy in breast cancer patients. Copyright (C) 2000 Elsevier Science Inc.

KW - Breast cancer

KW - Cell cycle regulator

KW - Cyclin D1

KW - Radiosensitivity

UR - http://www.scopus.com/inward/record.url?scp=0034662303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034662303&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(00)00525-3

DO - 10.1016/S0360-3016(00)00525-3

M3 - Article

C2 - 10889369

AN - SCOPUS:0034662303

VL - 47

SP - 1169

EP - 1176

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -